Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.
Prenetics Global Limited submitted a report describing a recent corporate update. On December 30, 2025, the company issued a press release announcing an update to its capital allocation strategy and the cessation of Bitcoin purchases. The report states that this press release is included as an exhibit and is being incorporated by reference into several existing Form F-3 and Form S-8 registration statements, allowing those registration documents to reflect the latest information about the company’s capital allocation approach.
Prenetics Global Limited reports that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. The notice of annual general meeting is furnished as Exhibit 99.1 to this report.
The company also states that this report is incorporated by reference into its existing registration statements on Form F-3 (File Nos. 333-274762, 333-276538 and 333-288824) and Form S-8 (File Nos. 333-279019, 333-271552 and 333-267956), so the information becomes part of those registration statement disclosures.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer for November 2025. The company reports that on November 24, 2025 it issued a press release announcing open market purchases of its shares by several members of its executive leadership team. The press release describing these executive share purchases is furnished as Exhibit 99.1 to the report.
Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market. On November 19, 2025, he purchased 20,000 Class A Ordinary Shares at $13.00 per share, for a total purchase price of $260,000. Following this transaction, his total holdings of Class A Ordinary Shares increased to 96,412 shares. This reflects a personal capital commitment by the CEO using his own funds rather than an issuance of new shares by the company.
Prenetics Global Limited (PRE) reported that its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, bought additional company stock on the open market. On November 18, 2025, he purchased 20,118 Class A Ordinary Shares at a price of $12.02 per share, for a total of about $242,000. Following this transaction, his holdings in the company’s Class A Ordinary Shares increased to 76,412, signaling a higher personal stake in Prenetics’ future performance.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, bought 30,000 Class A ordinary shares on the open market on November 14, 2025. He paid $13.29 per share, for a total purchase price of $398,821. Following this transaction, his total holdings increased to 75,553 Class A ordinary shares of the company. This filing simply records the executive share purchase and resulting ownership level.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, purchased 30,000 Class A Ordinary Shares in the open market on November 12, 2025 at $13.17 per share, for a total of $395,151. Following this transaction, his holdings increased to 45,553 Class A Ordinary Shares.
The purchase was disclosed via a Form 6-K and reflects an executive open-market buy.
Prenetics Global Limited filed a Form 6‑K furnishing a press release with its unaudited financial results for the third quarter ended September 30, 2025. The filing states that this report is incorporated by reference into the company’s existing Form F‑3 and Form S‑8 registration statements. The press release is attached as Exhibit 99.1.
Prenetics Global Limited closed a best efforts public offering of 2,722,642 Class A ordinary shares, each sold together with one Class A warrant and one Class B warrant at a combined price of $16.08 per unit. The company reported gross proceeds of approximately $44 million.
The Class A and Class B warrants are immediately exercisable for up to 2,722,642 shares each at exercise prices of $24.12 and $32.16, respectively, and have a five-year term from closing. Dominari Securities LLC acted as sole placement agent; compensation was an 8% cash success fee (reduced to 4% for company-introduced investors). Prenetics also issued placement agent warrants to purchase 131,829 shares at $16.08.
Prenetics plans to use proceeds for global expansion of IM8, development and implementation of its Bitcoin treasury strategy, working capital, and general corporate purposes. The transaction was conducted under an effective Form F-3 and closed on October 28, 2025.